Literature DB >> 34391755

Pulmonary Hypertension in the Context of Heart Failure With Preserved Ejection Fraction.

Chakradhari Inampudi1, Daniel Silverman1, Marc A Simon2, Peter J Leary3, Kavita Sharma4, Brian A Houston1, Jean-Luc Vachiéry5, Francois Haddad6, Ryan J Tedford7.   

Abstract

Heart failure with preserved ejection fraction (HFpEF) is the most common form of heart failure and frequently is associated with pulmonary hypertension (PH). HFpEF associated with PH may be difficult to distinguish from precapillary forms of PH, although this distinction is crucial because therapeutic pathways are divergent for the two conditions. A comprehensive and systematic approach using history, clinical examination, and noninvasive and invasive evaluation with and without provocative testing may be necessary for accurate diagnosis and phenotyping. After diagnosis, HFpEF associated with PH can be subdivided into isolated postcapillary pulmonary hypertension (IpcPH) and combined postcapillary and precapillary pulmonary hypertension (CpcPH) based on the presence or absence of elevated pulmonary vascular resistance. CpcPH portends a worse prognosis than IpcPH. Despite its association with reduced functional capacity and quality of life, heart failure hospitalizations, and higher mortality, therapeutic options focused on PH for HFpEF associated with PH remain limited. In this review, we aim to provide an updated overview on clinical definitions and hemodynamically characterized phenotypes of PH, pathophysiologic features, therapeutic strategies, and ongoing challenges in this patient population.
Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  diastolic heart failure; heart failure with preserved ejection fraction; left heart disease; pulmonary hypertension; right ventricle

Mesh:

Year:  2021        PMID: 34391755      PMCID: PMC8727853          DOI: 10.1016/j.chest.2021.08.039

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  82 in total

1.  Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease.

Authors:  Thomas M Gorter; Masaru Obokata; Yogesh N V Reddy; Vojtech Melenovsky; Barry A Borlaug
Journal:  Eur Heart J       Date:  2018-08-07       Impact factor: 29.983

2.  Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.

Authors:  James E Udelson; Gregory D Lewis; Sanjiv J Shah; Michael R Zile; Margaret M Redfield; John Burnett; John Parker; Jelena P Seferovic; Phebe Wilson; Robert S Mittleman; Albert T Profy; Marvin A Konstam
Journal:  JAMA       Date:  2020-10-20       Impact factor: 56.272

3.  Spironolactone for heart failure with preserved ejection fraction.

Authors:  Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

4.  The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.

Authors:  Masaru Obokata; Garvan C Kane; Yogesh N V Reddy; Vojtech Melenovsky; Thomas P Olson; Petr Jarolim; Barry A Borlaug
Journal:  Eur Heart J       Date:  2019-12-01       Impact factor: 29.983

5.  Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.

Authors:  Dalane W Kitzman; Peter Brubaker; Timothy Morgan; Mark Haykowsky; Gregory Hundley; William E Kraus; Joel Eggebeen; Barbara J Nicklas
Journal:  JAMA       Date:  2016-01-05       Impact factor: 56.272

Review 6.  A Fluid Challenge Test for the Diagnosis of Occult Heart Failure.

Authors:  Michele D'Alto; David Badesch; Eduardo Bossone; Barry A Borlaug; Evan Brittain; Marc Humbert; Robert Naeije
Journal:  Chest       Date:  2020-08-14       Impact factor: 9.410

7.  One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial.

Authors:  Sanjiv J Shah; Ted Feldman; Mark J Ricciardi; Rami Kahwash; Scott Lilly; Sheldon Litwin; Chris D Nielsen; Pim van der Harst; Elke Hoendermis; Martin Penicka; Jozef Bartunek; Peter S Fail; David M Kaye; Anthony Walton; Mark C Petrie; Niki Walker; Anupam Basuray; Steven Yakubov; Scott L Hummel; Stanley Chetcuti; Rhondalyn Forde-McLean; Howard C Herrmann; Daniel Burkhoff; Joseph M Massaro; John G F Cleland; Laura Mauri
Journal:  JAMA Cardiol       Date:  2018-10-01       Impact factor: 14.676

8.  Reduced Right Ventricular Sarcomere Contractility in Heart Failure With Preserved Ejection Fraction and Severe Obesity.

Authors:  M Imran Aslam; Virginia S Hahn; Vivek Jani; Steven Hsu; Kavita Sharma; David A Kass
Journal:  Circulation       Date:  2020-12-02       Impact factor: 29.690

9.  Transition from post-capillary pulmonary hypertension to combined pre- and post-capillary pulmonary hypertension in swine: a key role for endothelin.

Authors:  Richard W B van Duin; Kelly Stam; Zongye Cai; André Uitterdijk; Ana Garcia-Alvarez; Borja Ibanez; A H Jan Danser; Irwin K M Reiss; Dirk J Duncker; Daphne Merkus
Journal:  J Physiol       Date:  2018-06-21       Impact factor: 5.182

10.  Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study.

Authors:  Bradley A Maron; Evan L Brittain; Edward Hess; Stephen W Waldo; Anna E Barón; Shi Huang; Ronald H Goldstein; Tufik Assad; Bradley M Wertheim; George A Alba; Jane A Leopold; Horst Olschewski; Nazzareno Galiè; Gerald Simonneau; Gabor Kovacs; Ryan J Tedford; Marc Humbert; Gaurav Choudhary
Journal:  Lancet Respir Med       Date:  2020-07-27       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.